Purpose We report the biodistribution and radiation dosimetry of an integrin α v β 3 specific PET tracer 18 
Introduction
Angiogenesis is a key process in tumor growth and metastasis [1] . Targeted imaging of angiogenesis in vivo is an attractive strategy that represents a novel approach to noninvasively monitor angiogenesis and to assess the efficacy of antiangiogenic therapies. Integrin αvβ3 has been identified as a favorable target for imaging angiogenesis, and it plays a key role in the regulation of cellular activation, survival, and migration [2] . Various cyclic arginine-glycine-aspartic acid (RGD)-based peptide probes have been developed to probe integrin expression [3, 4] .
Positron emission tomography (PET) imaging allows noninvasive visualization and quantification of biological targets. A number of radiolabeled RGD peptides have been labeled with 18 F [5] , 64 Cu [6] , 68 Ga [7] , and 89 Zr [8] for integrin αvβ3-targeted PET imaging. 18 F is a medical cyclotronChunjing Yu and Donghui Pan contributed equally to this work.
* Min Yang ymzfk@yahoo.com.hk * Weixing Wan wwxjs@126.com produced positron isotope, and its half-life of 109.8 min matches well with the biological course of peptides. Therefore, 18 F is a good choice for labeling cyclic RGD peptides. Several 18 F-labeled RGD peptide tracers have been tested in oncologic patients, such as 18 F-galacto-RGD [9] and 18 F-AH111585 [10] . We recently successfully prepared 18 F-AlF-NOTA-PRGD2 (denoted as 18 F-Alfatide) [11] . It was shown that 18 F-Alfatide has promising imaging properties and pharmacokinetics that are comparable to those of 18 F-FPPRGD2 [12] . However, the glutamic acid-linked dimeric peptide with a free α-amine is labile due to the neighboring amine participation in the hydrolysis. Liquid chromatograph-mass spectrometry (LC-MS) analysis determined that the instability of thiourea derivatives formed from α-amine was caused by participation of a thiol group derived from thiourea, which is virtually the same as Edman degradation [13] except that the thiourea linkage is on the α-amine of glutamic acid instead of the N-terminal amine group [14] . We, thus, developed a much more stable new tracer 18 F-NOTA-E[PEG 4 -c(RGDfk)] 2 (denoted as Alfatide II, Fig. 1 ) for further biological evaluations [15, 16] . In the present study, the safety of 18 F-Alfatide II was evaluated, and the absorbed dose of 18 F-alfatide was estimated by analyzing the biodistribution data in healthy volunteers.
We also evaluated the value of 18 F-Alfatide II in patients with brain metastases.
Materials and methods

Radiopharmaceutical preparation
Synthesis of 18 F-alfatide II has been described previously [14] .
Safety
Safety data were collected before and after injection of 18 FAlfatide II. Safety data included vital signs (blood pressure, respiratory rate, heart rate, and body temperature); physical examination; ECG; laboratory parameters (blood routine, liver function and kidney function), and adverse events.
Healthy volunteers
Five healthy volunteers (3 M, 2 F; mean year ± SD, 35.0± 3.5, age range, 33-39 y; mean weight ± SD, 74.0±11.5, weight range, 62-85 kg) were included in the study. Each participant provided written informed consent using a form approved by the ethics committee of Wuxi No. 4 People's Hospital. Participants were generally healthy based on a physical examination and routine laboratory tests. Exclusion criteria consisted of conditions of mental illness, severe liver or kidney disease, and cardiovascular disease. Participants were also excluded if they were suffering from infectious diseases or were pregnant.
Patients
The study protocol was approved by the ethics committee of Wuxi No. 4 People's Hospital, and each patient gave written informed consent before the study. Nine patients (5 M, 4 F; age range, 27-71 y, mean age, 55±15 y) with cerebral metastases were included in this study. The brain metastases were confirmed by MRI or CT. The patient information is summarized in Table 1 . This study was registered at www.clinicaltrial.gov (NCT02441972).
PET/CT acquisition and PET image analysis
No specific subject preparation, such as fasting, was requested on the day of 18 F-Alfatide II imaging. PET/CT was performed on a Biograph 64 PET/CT scanner (Siemens Medical Solutions, Nuremberg, Germany). Healthy volunteers were positioned in the supine position on the scanner bed after injection of 18 F-Alfatide II (257±48 MBq, range, 203-296 MBq). Patients were positioned supine with their arms raised as was done with the standard CT practice, with the inferior border set to the thigh and the superior border set to the cranial bone. A continuous low-dose CT scan for attenuation correction was acquired in spiral mode using 120 kV, 170 mAs, slice thickness 2 mm, and pitch 0.8. No intravenous or oral contrast agent was administered. PET was performed immediately after the CT scan with the patient in the same position covering an area identical to that covered by the CT scan with 2 min per bed position (five to six bed positions depending on the size of the patient). The acquired time points included 40 s/bed position at 5, 10, and 15 min post-injection, and 2 min/bed position at 30, 45, and 60 min post-injection. PET image data were reconstructed on a 168×168 matrix using the ordered subset expectation maximization (OSEM) algorithm (three iterations, 21 subsets) and corrected for attenuation using the CT data. The PET/CT images (half-body-attenuated and nonattenuated PET, CT and fused images) were transferred to a multimodal work station (Syngo (TrueD); Siemens Medical Solutions) for analysis. Regions of interest (ROIs) were drawn manually using 3-D ellipsoid isocontours on each image with the assistance of the corresponding CT images.
For FDG PET, all nine patients fasted for at least 6 h before intravenous injection of 18 F-FDG (5.55 MBq/kg). Scanning was performed at 60 min after tracer administration. Images were taken from thigh to cranial bone with the Siemens PET/ CT scanner. Low-dose CT was performed for attenuation correction and lesion localization. Image acquisition was performed with 1.5 min per bed position. Brain image was acquired separately.
18 F-Alfatide II PET/CT was performed on the next day. No specific preparation was needed. The acquisition procedures were the same as those with FDG. ROIs were drawn manually on the site of brain metastases with the assistance of corresponding CT images by two experienced nuclear medical physicians. The results were expressed as maximum standardized uptake value (SUV max ).
Absorbed dose calculation
The dosimetry calculation was performed according to the EANM Dosimetry Guidance [17] . Based on the SUV of each organ, the decay uncorrected time-activity curve (TAC) was generated. The SUV values were converted to MBq/MBq based on organ weight from the adult male phantom (73.7 kg body weight) and the adult female phantom (56.9 kg body weight) provided by the OLINDA/EXM (version 1.1, Vanderbilt University, USA) [18, 19] . The timeintegrated activity coefficient (residence time) of each organ was determined by fitting the data using a bi-phase exponential model provided by the software. The urine bladder volume was determined by reconstructed PET/CT images, and the residence time was calculated by the trapezoidal method using 
Biodistribution
18 F-Alfatide II was quickly cleared out through the urinary system, indicated by the high radioactivity accumulation in the kidneys and bladder. In addition, the liver and spleen also showed moderate uptake, while the other organs had a low level of radioactivity distribution (Fig. 2) . The TACs of 18 F-Alfatide II in various major organs of the five healthy volunteers are presented in Fig. 3 . The highest SUVs in solid organs at 60 min after injection were found in the kidneys (6.32±1.09) and the spleen (6.26±0.68). Low activities in the brain, lung, and muscle were found with SUV of 0.07 ± 0.05, 0.27 ± 0.05, and 0.82 ± 0.17, respectively.
Absorbed dose calculation from PET/CT in healthy volunteers
The estimated absorbed dose of 18 F-Alfatide II for each organ derived from PET/CT images of healthy volunteers is shown in Table 2 . Since the bladder accumulated a high amount of radioactivity due to renal clearance of 18 FAlfatide II, the urinary bladder wall had the highest absorbed dose (0.1129±0.0629 mSv/MBq), which was followed by the liver (0.0670 ±0.0392 mSv/MBq), spleen (0.0669 ± 0.0121 mSv/MBq), and kidneys (0.0535 ± 0.0135 mSv/ MBq). The total effective dose equivalent (EDE) and 
Preliminary diagnostic value of 18 F-Alfatide II in brain metastases
Nine patients with a total of 20 metastatic brain tumors were enrolled in this study. Sixteen brain metastases were diagnosed by MRI. Four brain metastases were diagnosed by morphological imaging (CT or PET/CT) for patients without MRI. All the brain lesions were visualized by 18 
Discussion
Although several 18 F-labeled RGD tracers have entered clinical studies, the radiochemical syntheses are complex, and automation of these processes is challenging, which limit the widespread use of these traces in clinical settings [10, 20] . For example, the whole synthesis process of 18 F-Galacto-RGD takes around 200 min and that of 18 F-FPPRGD2 is about 120 min [21, 22] . With C-18 cartridge purification, 18 FAlfatide II can be produced with good radiochemical yield and high radiochemical purity within 20-30 min [23] . The fast-labeling process of 18 F-alfatide II makes it very attractive for clinical translation.
18 F-Alfatide II was found to be safe and well tolerated in all five healthy volunteers. No adverse events occurred following 18 F-Alfatide II injection, and no obvious changes in vital signs or clinical laboratory tests were found before and after injection of 18 F-alfatide II. The dosimetry calculations revealed an effective dose of less than 20 μSv/MBq. For a typical 255 MBq injected activity of 18 F-alfatide II, the whole body effective dose is 4.335 mSv, which is within the limit of 30 mSv specified by the FDA, for a single administration of radioactive material for research use. The absorbed dose is similar to other RGD-based PET imaging probes including Table 1 ). In the left frontal lobe metastatic lesion, 18 FAlfatide II shows a high tumor/background ratio of 9.45, but not 18 F-FDG. The c T 1 -, T 2 -and enhanced T 1 -weighted magnetic resonance (MR) images of the left frontal lobe metastasis. Arrows point to a brain metastatic lesion 18 F-galacto-RGD (0.0187 ±0.0024 mSv/MBq) [24] , 18 F-RGD-K5 (0.0150 ± 0.0010 mSv/MBq) [25] , and 18 F-AH111585 (0.0260±0.0040 mSv/MBq) [26] . All these data acquired in the healthy volunteers demonstrated the safety of 18 F-Alfatide II for further clinical applications.
Due to the excretion pathway and endogenous integrin expression, the distribution study of 18 F-alfatide II revealed relatively high radioactivity accumulation in the kidneys, spleen, and liver. Minimal radiotracer accumulation was found in the lung region, which justified several successful applications of RGD based tracers including 18 F-Alfatide in patients with lung cancer [27] [28] [29] . Due to the low background, a high tumor/non-tumor ratio can be achieved, which facilitates lesion detection. For example, in our previous study with a small population of patients with lung cancer, all lesions can be visualized on 18 F-Alfatide PET [27] . Besides, 18 F-Alfatide PET may provide additional information for screening tumorinduced inflammation and scrofula lesions.
Although 18 F-FDG PET plays a significant role in clinical oncology due to increased glucose metabolism in cancer cells, its sensitivity and specificity in the assessment of brain tumors is limited by high physiologic glucose uptake in normal brain tissue [30] . Consequently, other radiotracers for brain tumor detection have been intensively investigated for differential diagnosis, therapy response monitoring, and prognosis prediction [31] . In several preclinical studies, RGD-based tracers demonstrated very high imaging quality in visualization of xenografted or orthotopic brain tumors [32, 33] . In healthy volunteers, we observed very low tracer uptake in normal brain with a SUV of 0.068±0.048 at 60 min after tracer injection, indicating that 18 F-alfatide II does not penetrate the blood-brain barrier (BBB). Thus, we hypothesized that 18 Falfatide II PET may allow clear diagnosis and evaluation of tumor metastases in the brain. Another rationale for this study is that angiogenesis, the target of 18 F-Alfatide II, is one of the key pathophysiologic processes in brain metastases [34] . Consequently, all 20 metastatic brain lesions were clearly visualized by 18 F-Alfatide II PET due to the extremely low background from the surrounding tissue. By contrast, only ten lesions were detectable by 18 F-FDG PET with a much lower tumor/background ratio. These data demonstrated the great value of 18 F-Alfatide II in metastatic brain tumor detection. The increased uptake of 18 F-alfatide II may be a result of increased angiogenesis and integrin expression. We noticed Table 1 ). CT image shows normal density compared with the contralateral lobe. In the brain metastatic region 18 F-Alfatide II shows a high tumor/background ratio of 22.8, but no tumor contrast is identified with 18 F-FDG PET Table 1 ). CT image shows high density with peripheral edema. The right temporal metastasis shows intense 18 FAlfatide II uptake with a tumor/background ratio of 13, and 18 F-FDG PET shows no increased uptake the big variance of the values of SUV max , which may reflect the difference of integrin expression in lesions of different origins and indicate great inter-and intra-individual variation of αvβ3 expression in cancer patients. Due to the lack of histological data in this study, we were not able to correlate the imaging results of 18 F-Alfatide II PET with the expression level of integrin αvβ3.
One limitation of this study is the limited number of healthy volunteers and cancer patients. In heathy volunteers, most of RGD-based tracers showed a similar pharmacokinetic pattern as to the biodistribution of the radioactivity in major organs [24] [25] [26] . By taking the previously published results of the other RGD tracers and the data in this study from the healthy volunteers into consideration, we believe the 18 F-Alfatide II is a safe PET tracer. Based on our patient data, the accurate diagnosis and prognosis value of 18 F-Alfatide II PET also warrant further larger scale clinical investigations.
Conclusion
18 F-Alfatide II is a safe integrin αvβ3 PET tracer. The biodistribution and radiation dosimetry of 18 F-Alfatide II are similar to other 18 F-radiotracers used for PET imaging of integrin αvβ3. The observed effective dose suggests that 18 F-alfatide II is feasible for human studies. 18 F-Alfatide II has a potential value in finding brain metastases as a biomarker of angiogenesis.
